Health Team
FDA OK's Emergent BioSolutions plant to resume manufacturing J&J's Covid-19 vaccine
Emergent BioSolutions announced Thursday that the US Food and Drug Administration will allow it to resume the manufacturing of the drug substance that goes into Johnson & Johnson's Covid-19 vaccine.
Posted — UpdatedBy Jen Christensen and Nadia Kounang, CNN
CNN — Emergent BioSolutions announced Thursday that the US Food and Drug Administration will allow it to resume the manufacturing of the drug substance that goes into Johnson & Johnson's Covid-19 vaccine.
According to an administration official, the Baltimore plant has not been fully authorized yet, and while production can resume, the FDA will still need to inspect the individual lots of vaccine before they go out for shipment and can be administered.
This is a developing story and will be updated.
The-CNN-Wire™ & © 2021 Cable News Network, Inc., a WarnerMedia Company. All rights reserved.
Copyright 2024 by Cable News Network, Inc., a Time Warner Company. All rights reserved.